Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2010-7-16
pubmed:abstractText
B-cell lymphoma is a clonal expansion of neoplastic cells that may result in fatal outcomes. Here, we report the in vivo targeting and growth inhibition of aggressive A20 murine B-cell lymphoma by idiotype-specific peptide pA20-36. pA20-36 was selected from random peptide libraries and bound specifically to the B-cell receptor (BCR) of A20 cells in mice engrafted with A20 lymphoma, as shown by histology and positron emission tomographic analysis. BCR cross-linking of A20 cells with pA20-36 resulted in massive apoptosis of targeted tumor cells and in an increased survival of the diseased animals without any detectable evidence of toxicity. The pA20-36 treatment reverted the immune suppression of the tumor microenvironment as shown by reduced expression of vascular endothelial growth factor, interleukin-10, and transforming growth factor-beta cytokines together with a lower number of CD11b+Gr-1+ inhibitor myeloid-derived suppressor cells and Foxp3+CD4+ Treg cells. Furthermore, pA20-36 treatment was associated with an increased number of tumor-infiltrating, activated CD8+ T cells that exerted a tumor-specific cytolytic activity. These findings show that a short peptide that binds specifically to the complementarity-determining regions of the A20 BCR allows in vivo detection of neoplastic cells together with significant inhibition of tumor growth in vivo.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1528-0020
pubmed:author
pubmed:issnType
Electronic
pubmed:day
15
pubmed:volume
116
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
226-38
pubmed:meshHeading
pubmed-meshheading:20363775-Animals, pubmed-meshheading:20363775-Antibodies, Anti-Idiotypic, pubmed-meshheading:20363775-Antibodies, Monoclonal, pubmed-meshheading:20363775-Antibody Specificity, pubmed-meshheading:20363775-Antineoplastic Agents, pubmed-meshheading:20363775-Cell Line, Tumor, pubmed-meshheading:20363775-Cell Proliferation, pubmed-meshheading:20363775-Cell Separation, pubmed-meshheading:20363775-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:20363775-Flow Cytometry, pubmed-meshheading:20363775-Immunoglobulin Idiotypes, pubmed-meshheading:20363775-Immunotherapy, pubmed-meshheading:20363775-Lymphoma, B-Cell, pubmed-meshheading:20363775-Mice, pubmed-meshheading:20363775-Mice, Inbred BALB C, pubmed-meshheading:20363775-Microscopy, Confocal, pubmed-meshheading:20363775-Peptide Library, pubmed-meshheading:20363775-Peptides, pubmed-meshheading:20363775-Positron-Emission Tomography, pubmed-meshheading:20363775-Receptors, Antigen, B-Cell, pubmed-meshheading:20363775-Surface Plasmon Resonance
pubmed:year
2010
pubmed:articleTitle
In vivo targeting and growth inhibition of the A20 murine B-cell lymphoma by an idiotype-specific peptide binder.
pubmed:affiliation
Department of Experimental and Clinical Medicine, University of Catanzaro Magna Graecia, Catanzaro, Italy.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't